US drug company Marathon Pharmaceuticals has received approval for a drug to treat a rare muscle-wasting disease, for which it will charge $89,000 (â‚¹59 lakh) annually. This marks around 6,000% increase in price as against countries like Canada, where patients can avail the drug for between $1,000-$2,000. According to analysts, the company showed restraint in how it priced the drug.